Erlotinib in Treating Patients With Recurrent or Progressive Glioblastoma Multiforme
Part of paid clinical trials in Cleveland, Ohio.
- Sponsor
- The Cleveland Clinic
- Study ID
- NCT00054496
- Phase
- PHASE2
- Status
- Unknown
Conditions
- Brain and Central Nervous System Tumors
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- erlotinib hydrochloride — DRUG
Study Details
RATIONALE: Erlotinib may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: Phase II trial to study the effectiveness of erlotinib in treating patients who have recurrent or progressive glioblastoma multiforme.
Key Dates
- First listed
- Feb 6, 2003
- Start date
- Aug 31, 2002
- Status verified
- Dec 2006
Study Design
- Enrollment
- 73 participants (estimated)
- Primary purpose
- TREATMENT
Primary Outcome Measure
Response rate
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Cleveland Clinic Taussig Cancer Center | Cleveland | Ohio | 44195 | Clinical Trials Office - Cleveland Clinic Taussig Cancer Cente 866-223-8100 |
Find similar trials in Cleveland, OH
By research site
Related Studies
- Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent GlioblastomaPHASE1/PHASE2 · Recruiting · National Institute of Neurological Disorders and Stroke (NINDS) · Bethesda, Maryland